ACHILLION PHARMACEUTICALS
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
ACHILLION PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
1998-01-01
Address:
Blue Bell, Pennsylvania, United States
Country:
United States
Website Url:
http://www.achillion.com
Total Employee:
51+
Status:
Closed
Contact:
+215-709-3040
Email Addresses:
[email protected]
Total Funding:
468.71 M USD
Technology used in webpage:
Domain Not Resolving SPF Amazon IPv6 Microsoft Amazon Route 53 Amazon CloudFront Akamai Hosted Comcast Mimecast
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Quaker BioVentures
Quaker BioVentures investment in Post-IPO Equity - Achillion Pharmaceuticals
Clarus Ventures
Clarus Ventures investment in Post-IPO Equity - Achillion Pharmaceuticals
Domain Associates
Domain Associates investment in Post-IPO Equity - Achillion Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Post-IPO Equity - Achillion Pharmaceuticals
ING Furman Selz Asset Management
ING Furman Selz Asset Management investment in Venture Round - Achillion Pharmaceuticals
Schroder Ventures
Schroder Ventures investment in Venture Round - Achillion Pharmaceuticals
Connecticut Innovations
Connecticut Innovations investment in Venture Round - Achillion Pharmaceuticals
Bear Stearns
Bear Stearns investment in Venture Round - Achillion Pharmaceuticals
Oakwood Medical Investors
Oakwood Medical Investors investment in Venture Round - Achillion Pharmaceuticals
KBL Healthcare Ventures
KBL Healthcare Ventures investment in Venture Round - Achillion Pharmaceuticals
Official Site Inspections
http://www.achillion.com
- Host name: server-18-160-10-88.iad12.r.cloudfront.net
- IP address: 18.160.10.88
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Achillion Pharmaceuticals"
Achillion Pharmaceuticals - Crunchbase Company Profile & Funding
Organization. Achillion Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. A biopharmaceutical company …See details»
Achillion Pharmaceuticals, Inc. | LinkedIn
Achillion Pharmaceuticals, Inc. | 5,418 followers on LinkedIn. COMPLEMENT FOCUSED. PATIENT DRIVEN. | On January 28, 2020, Achillion Pharmaceuticals was acquired by Alexion Pharmaceuticals, Inc. As ...See details»
Achillion Pharmaceuticals Inc. - AnnualReports.com
Achillion Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.See details»
Achillion Shareholders Approve Agreement to be Acquired by …
Dec 19, 2019 --Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated …See details»
Achillion Company Profile 2024: Valuation, Investors ... - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Achillion. Use the PitchBook Platform to explore the full profile.See details»
Alexion Completes Acquisition of Achillion - Business Wire
Jan 28, 2020 Contacts. Alexion Contacts: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, …See details»
Alexion fortifies rare blood disorder drugs business with Achillion ...
Oct 16, 2019 Alexion Pharmaceuticals Inc <ALXN.O> on Wednesday agreed to buy smaller biotech Achillion Pharmaceuticals Inc <ACHN.O> in a deal initially valued at $930 million, as …See details»
Alexion wraps up $930m acquisition of Achillion
Alexion Pharmaceuticals has completed the acquisition of clinical-stage biopharmaceutical company Achillion Pharmaceuticals for around $930m.See details»
Alexion to Acquire Achillion for $930M+, Expanding …
Oct 16, 2019 Alexion Pharmaceuticals CEO Ludwig Hantson, PhD. Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for $930 million-plus, the companies said today, in a deal designed to ...See details»
Achillion Pharmaceuticals - Contacts, Employees, Board Members ...
Organization. Achillion Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of …See details»
Alexion Completes Acquisition Of Achillion - Pharma Journalist
Jan 28, 2020 Alexion Pharmaceuticals, Inc. announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule …See details»
Global Biopharmaceutical Company Alexion Completes …
The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development …See details»
Achillion Pharmaceuticals - Craft
Achillion Pharmaceuticals is a company engaged in the discovery, development and commercialization of treatments for infectious diseases. It offers a portfolio of orally …See details»
Alexion to shell out $930m to acquire Achillion Pharmaceuticals
Alexion to pay $930m to acquire Achillion Pharmaceuticals. Alexion Pharmaceuticals has agreed to acquire Achillion Pharmaceuticals for an upfront payment of around $930m, or $6.30 per …See details»
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra …
Jan 9, 2018 Background of the Company. Achillion is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases.The …See details»
Alexion inks deal to acquire Achillion for $930M upfront
Oct 16, 2019 Alexion has struck a deal to buy Achillion for $930 million upfront. The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway …See details»
The A-Team: Alexion to acquire Achillion in $930M deal
Two pioneers of the Elm City’s bioscience industry are about to become one. Alexion Pharmaceuticals Inc. said Wednesday morning it plans to acquire fellow New Haven-born …See details»
Alexion Completes Acquisition of Achillion - Nasdaq
Jan 28, 2020 Alexion Pharmaceuticals, Inc. today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule …See details»
Alexion to Acquire Achillion for $930 Million - pharmtech.com
Oct 16, 2019 The transaction gives Alexion access to Achillion’s portfolio of oral small-molecule Factor D inhibitors to treat people with complement alternative pathway-mediated rare diseases.See details»
Achilles International
Achilles International offers athletic programs and social connections for individuals with disabilities, promoting well-being and self-confidence.See details»